
Opinion|Videos|July 16, 2024
Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies
Atopic dermatitis experts examine factors that impact coverage decisions for atopic dermatitis (AD) treatments, address challenges providers encounter (such as step-therapy and prior authorization) and offer strategies to streamline the prior authorization process for topical AD therapies.
Advertisement
Episodes in this series

- In addition to cost, what factors influence coverage decisions for AD treatments?
- How do step-therapy protocols and prior authorization approval process influence the prescribing patterns of topical therapies (and progressing to systemic therapies) for AD among healthcare providers?
- What strategies can healthcare providers implement to streamline the PA approval process for topical AD therapies and reduce administrative burdens while still ensuring cost-effective care?
- Please discuss the burden providers face in terms of workload perspective, staffing constraints, etc, and what this means for patients
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Amid SOHO Data, Reviewers of BTK Inhibitors in MCL Call for Trials
2
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
3
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
4
Cross-Trial Vitiligo Data: What Payers Can and Can't Compare
5





